Neutrophil-Derived Myeloperoxidase and Hypochlorous Acid Critically Contribute to 20-Hydroxyeicosatetraenoic Acid Increases that Drive Postischemic Angiogenesis

Autor: Juan A, Azcona, Samantha, Tang, Elizabeth, Berry, Frank F, Zhang, Radha, Garvey, John R, Falck, Michal Laniado, Schwartzman, Tao, Yi, Thomas M, Jeitner, Austin M, Guo

Publikováno v: J Pharmacol Exp Ther

Compensatory angiogenesis is an important adaptation for recovery from critical ischemia. We recently identified 20-hydroxyeicosatetraenoic acid (20-HETE) as a novel contributor of ischemia-induced angiogenesis. However, the precise mechanisms by whi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595794d0963eda57adce6a9d9a0c7639
https://doi.org/10.1124/jpet.121.001036

Abstract 122: 20-HETE Antagonists Normalize Large Artery Stiffness and Systolic Blood Pressure in Metabolic Syndrome

Autor: Amanda A Soler, Ian Hunter, Gregory Joseph, Rebecca Hutcheson, Brenda Hutcheson, Jenny Yang, Frank F Zhang, Sachindra R Joshi, Chastity Bradford, Katherine H Gotlinger, Rachana Maniyar, John R Falck, Spencer Proctor, Michal L Schwartzman, Sachin A Gupte, Petra Rocic

Publikováno v: Hypertension. 70

Large artery stiffness is a causal factor in development of systolic hypertension. 20-hydroxyeicosatetraeonic acid (20-HETE), a cytochrome CYP450-derived arachidonic acid metabolite, is known to be elevated in resistance arteries in hypertensive anim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ba09bf9ba8074808f80d0867ebd7a4b
https://doi.org/10.1161/hyp.70.suppl_1.122

Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis.

Autor: Guzauskas GF; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Tabrizi SJ; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Long JD; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Arnesen A; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Hamilton JL; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Claassen DO; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Munetsi LR; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Malik S; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Rodríguez-Santana I; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Ali TM; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA., Zhang F; The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA.

Publikováno v: Neurology. Clinical practice [Neurol Clin Pract] 2024 Oct; Vol. 14 (5), pp. e200340. Date of Electronic Publication: 2024 Aug 15.

Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC.

Autor: Lee M; 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York., Liu J; 2Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York., Miao E; 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York., Wang S; 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York., Zhang F; 3Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Wei J; 3Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Chung J; 4Department of Health Information Management, Montefiore Medical Center, Bronx, New York., Xue X; 2Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York., Halmos B; 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York., Hosgood HD; 2Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York., Cheng H; 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York.

Publikováno v: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2023 Dec; Vol. 21 (12), pp. 1269-1280.e5.

Epstein-Barr Virus-Associated Pulmonary Leiomyoma in a Patient With Untreated Human Immunodeficiency Virus Infection.

Autor: Sharma S; Department of Internal Medicine, Louisiana State University Health, Shreveport, Louisiana, USA., Ulicny J; Department of Internal Medicine, Louisiana State University Health, Shreveport, Louisiana, USA., Thuzar M; Department of Pathology, Louisiana State University Health, Shreveport, Louisiana, USA., Aguiar RS; Department of Pathology, Louisiana State University Health, Shreveport, Louisiana, USA., Sharkey S; Department of Pulmonary and Critical Care, Louisiana State University Health, Shreveport, Louisiana, USA., Zhang F; Department of Pulmonary and Critical Care, Louisiana State University Health, Shreveport, Louisiana, USA., Chambers D; Department of Pulmonary and Critical Care, Louisiana State University Health, Shreveport, Louisiana, USA., Malek AE; Division of Infectious Disease, Department of Internal Medicine, Louisiana State University Health, Shreveport, Louisiana, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2023 Oct 03; Vol. 10 (10), pp. ofad492. Date of Electronic Publication: 2023 Oct 03 (Print Publication: 2023).